Orexo AB
STO:ORX

Watchlist Manager
Orexo AB Logo
Orexo AB
STO:ORX
Watchlist
Price: 19.26 SEK -0.1% Market Closed
Market Cap: 663.5m SEK
Have any thoughts about
Orexo AB?
Write Note

Orexo AB
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Orexo AB
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Orexo AB
STO:ORX
Other Liabilities
kr13.4m
CAGR 3-Years
7%
CAGR 5-Years
10%
CAGR 10-Years
5%
Calliditas Therapeutics AB
STO:CALTX
Other Liabilities
kr165.7m
CAGR 3-Years
36%
CAGR 5-Years
585%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Other Liabilities
kr42.4m
CAGR 3-Years
256%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Other Liabilities
kr10m
CAGR 3-Years
N/A
CAGR 5-Years
30%
CAGR 10-Years
N/A
IRLAB Therapeutics AB
STO:IRLAB A
Other Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Other Liabilities
kr1.5m
CAGR 3-Years
253%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Orexo AB
Glance View

Market Cap
663.5m SEK
Industry
Pharmaceuticals

Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. The company is headquartered in Uppsala, Uppsala and currently employs 121 full-time employees. The company went IPO on 2005-11-09. The company focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The firm has four commercialized products, several projects developed in partnership, as well as three development programs. The firm's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The firm operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.

ORX Intrinsic Value
39.21 SEK
Undervaluation 51%
Intrinsic Value
Price

See Also

What is Orexo AB's Other Liabilities?
Other Liabilities
13.4m SEK

Based on the financial report for Sep 30, 2024, Orexo AB's Other Liabilities amounts to 13.4m SEK.

What is Orexo AB's Other Liabilities growth rate?
Other Liabilities CAGR 10Y
5%

Over the last year, the Other Liabilities growth was 35%. The average annual Other Liabilities growth rates for Orexo AB have been 7% over the past three years , 10% over the past five years , and 5% over the past ten years .

Back to Top